Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H, Hou L, Wu C, Zhu Y, Jiang G, Zhu H, Zhou Y, Fang S, Zhang T, Hu L, Li J, Liu Y, Zhang H, Zhang B, Ding L, Robles AI, Rodriguez H, Gao D, Ji H, Zhou H, Zhang P. Liu Q, et al. Among authors: zhang l, zhang b, zhang p, zhang t, zhang j, zhang h. Cell. 2024 Jan 4;187(1):184-203.e28. doi: 10.1016/j.cell.2023.12.004. Cell. 2024. PMID: 38181741
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X, Sun L, Song N, He W, Xie B, Hu J, Zhang J, Yang J, Dai J, Bian D, Xia H, Sun F, Xiong A, Luo J, Zhang L, Yu H, Liu M, Liu H, Wang H, Zhang H, Chen C, Wu C, Duan L, Zhu Y, Zhang P, Jiang G. Zhu X, et al. Among authors: zhang l, zhang p, zhang j, zhang h. BMC Med. 2022 Dec 30;20(1):493. doi: 10.1186/s12916-022-02696-4. BMC Med. 2022. PMID: 36581917 Free PMC article. Clinical Trial.
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. Liu NN, et al. Among authors: zhang p, zhang ll. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21. Cancer Cell. 2023. PMID: 37738973
The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.
Shen Z, Teng M, Han L, Bian D, Zhang J, Zhu X, Qing Y, Hu S, Chen Y, Yao W, Yu H, Zhang L, Zhang P. Shen Z, et al. Among authors: zhang l, zhang p, zhang j. Cancer Immunol Immunother. 2023 Dec;72(12):4235-4247. doi: 10.1007/s00262-023-03560-x. Epub 2023 Nov 6. Cancer Immunol Immunother. 2023. PMID: 37932425 Free PMC article.
Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center.
Zeng A, Xiong Y, Zhang J, Yu H, Zhang L, Bian D, Han L, Wang J, Chen Y, Shaik MS, Zhang P, Dai J. Zeng A, et al. Among authors: zhang l, zhang p, zhang j. Transl Lung Cancer Res. 2024 Jan 31;13(1):16-33. doi: 10.21037/tlcr-23-606. Epub 2024 Jan 29. Transl Lung Cancer Res. 2024. PMID: 38405002 Free PMC article.
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. Liu NN, et al. Among authors: zhang p, zhang ll. Cancer Cell. 2024 Feb 12;42(2):318-322. doi: 10.1016/j.ccell.2024.01.005. Cancer Cell. 2024. PMID: 38350423 No abstract available.
124,452 results
You have reached the last available page of results. Please see the User Guide for more information.